Dr. Ethel Rubin is a biotech strategy and finance executive with over 20 years of experience at the intersection of healthcare investment and commercialization. With a proven track record in leading high-impact business and corporate development activities, driving product and portfolio strategies, and engaging with investors and industry partners, she currently leads a team of venture professionals helping NIH portfolio companies navigate rapid growth cycles, prepare for capital raise, progress to valuation inflection points and exit.  In addition, she is an active business consultant to biotech, partnering with strong scientific and clinical teams to bridge the gap between breakthrough research and institutional-grade commercial strategy, building the financial architecture and strategic roadmap necessary to attract institutional investment or scale to an exit. In previous roles as an EIR for the NHLBI, she deployed a $40M pre-seed fund, resulting in over $1B in exits. From 2009-2015 she led global clinical strategy, external innovation and medical affairs at Medtronic, plc, with a focus on interventional technologies including the fast growing Afib ablation business. Prior to that, she was CSO/COO of two successful early stage companies: BioFortis, Inc. (acquired by IQVIA) and CSA Medical, Inc. Over the course of her career, Dr. Rubin took part in over 25 commercial product launches, was instrumental in multiple M&As, partnerships & collaborations, and capital raises totaling more than $2B. Ethel currently sits on the Board of a multinational biotech company, Volition Rx (NYSE:VNRX), a world leader in nucleosome detection and quantitiation, and was previously a Director at Innara Health, Inc., where she helped attract strategic investment and exit in 3 years via acquisition by Cardinal Health (NYSE:CAH). She is an advisor or mentor to numerous companies through both private engagement as well as NYU Stern School of Business’ Endless Frontier Labs. Dr. Rubin earned a PhD in Biochemistry and Biophysics from the University of Rochester School of Medicine & Dentistry and was a research fellow at Johns Hopkins University School of Medicine, where she led independent breast cancer research that identified developmental gene re-expression in adult tumors. She earned a certificate in Corporate Governance from The George Washington University School of Business and is an LP in VC funds focused on women’s health as well as an advisor to First Bight Ventures. Ethel maintains media presence as a sought-after speaker, moderator or pitch judge. Check out her articles on www.linkedin.com/in/ethelrubinphd/.